MAP2K7 and Miyoshi myopathy: Nevertheless, a promising option is the combination of MEK inhibitors with inhibitors of the PI3K pathway, thereby blocking two key signaling pathways of NRAS [67], which has already been shown for NRAS-mutant MM.